Understanding sex differences in adverse drug reactions to drugs for psychosis could potentially guide clinicians in optimal drug choices.
Aims:
By applying a text-mining approach, this study aimed to investigate the relationship between drugs for psychosis and biological sex differences in frequencies and co-occurrences of potential adverse drug events (ADEs).
Methods:
Electronic patient records of a psychiatric population (1427 men and 727 women) were text mined for potential ADEs. The relative risk of experiencing specific ADEs and co-occurrence of ADEs were calculated for each sex.
Results:
Findings included 55 potential ADEs with significantly different frequencies between the two sexes. Of these, 20 were more frequent in men, with relative risks of 1.10–7.64, and 35 were more frequent in women, with relative risks of 1.19–21.58. Frequent potential ADEs were psychiatric symptoms, including sexual dysfunction and disturbances in men, and gastrointestinal symptoms, suicidal and self-injurious behaviour and hyperprolactinemia-related events in women. Mention of different hyperprolactinemia-related ADEs often co-occurred in female patients but not in male patients.
Conclusion:
Several known sex-related ADEs were identified, as well as some previously not reported. When considering the risk–benefit profile of drugs for psychosis, the patient’s sex should be considered.
AichhornWWhitworthABWeissEM, et al. (2006) Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?Drug Saf29: 587–598.
2.
BarbuiCNosèMBindmanJ, et al. (2005) Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol25: 521–526.
3.
BobesJGarcía-PortillaMPRejasJ, et al. (2003) Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther29: 125–147.
4.
BrownEGWoodLWoodS (1999) The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf20: 109–117.
5.
ChavesACSeemanMV (2006) Sex selection bias in schizophrenia antipsychotic trials. J Clin Psychopharmacol26: 489–494.
6.
CorrellCU (2007) Acute and long-term adverse effects of antipsychotics. CNS Spectr12: 10–14.
7.
CrawfordMBDeLisiLE (2016) Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry29: 211–217.
8.
ErikssonRJensenPBFrankildS, et al. (2013) Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text. J Am Med Inform Assoc20: 947–953.
9.
ErikssonRWergeTJensenLJ, et al. (2014) Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population. Drug Saf37: 237–247.
10.
EugeneARMasiakJ (2017) A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nord J Psychiatry71: 417–424.
11.
FoxKRMillnerAJMukerjiCE, et al. (2017) Examining the role of sex in self-injurious thoughts and behaviors. Clin Psychol Rev66: 3–11.
12.
FranconiFCampesiI (2014) Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol171: 580–594.
13.
GrossmanLHarrowMRosenC, et al. (2006) Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv57: 844–850.
14.
HaackSSeeringerAThürmannPA, et al. (2009) Sex-specific differences in side effects of psychotropic drugs: genes or gender?Pharmacogenomics10: 1511–1526.
15.
HarpazRCallahanATamangS, et al. (2014) Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf37: 777–790.
16.
HowardLMEhrlichAMGamlenF, et al. (2017) Gender-neutral mental health research is sex and gender biased. Lancet Psychiatry4: 9–11.
17.
HuangYLMoonJSegalJB (2014) A comparison of active adverse event surveillance systems worldwide. Drug Saf37: 581–596.
18.
IversenTSJSteenNEDiesetI, et al. (2018) Side effect burden of antipsychotic drugs in real life – impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry82: 263–271.
19.
KraalAZWardKMEllingrodVL (2017) Sex differences in antipsychotic related metabolic functioning in schizophrenia spectrum disorders. Psychopharmacol Bull47: 8–21.
20.
KreimeyerKFosterMPandeyA, et al. (2017) Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. J Biomed Inform73: 14–29.
21.
La TorreAConcaADuffyD, et al. (2013) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry46: 201–208.
22.
LangeBMuellerJKLewekeFM, et al. (2017) How gender affects the pharmacotherapeutic approach to treating psychosis – a systematic review. Expert Opin Pharmacother18: 351–362.
23.
LauSLMuirCAssurY, et al. (2016) Predicting weight gain in patients treated with clozapine. J Clin Psychopharmacol36: 120–124.
24.
LiQChenDLiuT, et al. (2016) Sex differences in body mass index and obesity in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol36: 643–648.
25.
LuoYThompsonWKHerrTM, et al. (2017) Natural language processing for EHR-based pharmacovigilance: a structured review. Drug Saf40: 1075–1089.
26.
MarazzitiDBaroniSPicchettiM, et al. (2013) Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex. CNS Spectr18: 118–127.
27.
Martínez-OrtegaJMJuradoDGutiérrez-RojasL, et al. (2012) Stability of sex differences by diagnosis in psychiatric hospitalizations. Psychiatry Res198: 161–163.
28.
MendrekAStipE (2011) Sexual dimorphism in schizophrenia: is there a need for gender-based protocols?Expert Rev Neurother11: 951–959.
29.
MontalvoINadalRArmarioA, et al. (2017) Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. Aust N Z J Psychiatry52: 585–595.
30.
NielsenJMeyerJM (2012) Risk factors for ileus in patients with schizophrenia. Schizophr Bull38: 592–598.
31.
PrusatorDKChangL (2017) Sex-related differences in GI disorders. Handb Exp Pharmacol239: 177–192.
32.
RazLMillerVM (2013) Considerations of sex and gender differences in preclinical and clinical trials. Handb Exp Pharmacol214: 127–147.
33.
RodenburgEMStrickerBHCVisserLE (2011) Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol71: 95–104.
34.
RoitmannEErikssonRBrunakS (2014) Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events. Front Physiol5: 332.
35.
RoqueFSJensenPBSchmockH, et al. (2011) Using electronic patient records to discover disease correlations and stratify patient cohorts. PLoS Comput Biol7: e1002141.
36.
SchoretsanitisGDrukkerMVan OsJ, et al. (2018) No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment. Acta Psychiatr Scand138: 110–122.
37.
SeemanMV (2009) Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull35: 937–948.
38.
SeemanMV (2010) Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatr Nurses Assoc16: 21–29.
39.
ShannonPMarkielAOzierO, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research13: 2498–2504.
40.
SoldinOPMattisonDR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet48: 143–157.
41.
SoldinOPChungSHMattisonDR (2011) Sex differences in drug disposition. J Biomed Biotechnol2011: 14.
42.
SolmiMMurruAPacchiarottiI, et al. (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag13: 757–777.
43.
WestawayKSluggettJKAldermanC, et al. (2016) Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. Int J Evid Based Healthc14: 104–112.
44.
WestergaardDMoseleyPSørupFKH, et al. (2019) Population-wide analysis of differences in disease progression patterns in men and women. Nat Commun10: 666.
45.
World Health Organization (2002) Integrating Gender Perspectives in the Work of WHO: WHO Gender Policy. Geneva: World Health Organization.
46.
World Health Organization (2016) International Statistical Classification of Diseases and Related Health Problems. 10th revision. 5th ed.Geneva: World Health Organization.
47.
YoungSLTaylorMLawrieSM (2015) ‘First do no harm.’ A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol29: 353–362.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
